Drug
Firsekibart
Firsekibart is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_4
1
25%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting2
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
recruiting125%
active_not_recruiting125%
not_yet_recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
NCT07686770
active_not_recruitingphase_4
Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus
NCT07381465
not_yet_recruitingnot_applicable
24-Week Recurrence Rate of Gout Following Firsekibart Treatment
NCT07625514
recruiting
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
NCT07191444
Clinical Trials (4)
Showing 4 of 4 trials
NCT07686770Phase 2
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
NCT07381465Phase 4
Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus
NCT07625514Not Applicable
24-Week Recurrence Rate of Gout Following Firsekibart Treatment
NCT07191444
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4